Plain-English translation of NCT04140487 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of three medications—, , and —to treat adults with certain blood cancers or bone marrow disorders that have a specific genetic change called an FLT3 mutation. The study is divided into two phases: first, researchers will find the safest and most effective doses of this medication combination, and then they will test how well the treatment works for different groups of patients. The goal is to help people whose cancer has come back or stopped responding to previous treatments.
People with these blood cancers that carry an FLT3 mutation often have limited treatment options, especially if their disease returns or stops responding to standard care. This trial exists to see whether combining these three medications—which work in different ways to fight cancer cells—might be more effective than treatments used today.
You likely qualify if…
You likely don't qualify if…
You will receive three medications: (given as an injection into the skin or through an IV for 7 days each month), (a pill taken by mouth daily), and (a pill taken by mouth daily). Treatment cycles last 28 days, and you may receive up to 24 cycles if the treatment is working and you are tolerating it well. You will have regular visits to your doctor to check how you are responding and watch for any side effects. After treatment ends, you will return for a follow-up visit 30 days later, and then every 6 months to monitor your health.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States